Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis

Citations Over TimeTop 1% of 2004 papers

Abstract

The decisions made by the National Institute for Clinical Excellence (NICE) give rise to two questions: how is cost-effectiveness evidence used to make judgements about the 'value for money' of health technologies? And how are factors other than cost-effectiveness taken into account? The aim of this paper is to explore NICE's cost-effectiveness threshold(s) and the tradeoffs between cost effectiveness and other factors apparent in its decisions. Binary choice analysis is used to reveal the preferences of NICE and to consider the consistency of its decisions. For each decision to accept or reject a technology, explanatory variables include: the cost per life year or per QALY gained; uncertainty regarding cost effectiveness; the net cost to the NHS; the burden of disease; the availability (or not) of alternative treatments; and specific factors indicated by NICE. Results support the broad notion of a threshold, where the probability of rejection increases as the cost per QALY increases. Cost effectiveness, together with uncertainty and the burden of disease, explain NICE decisions better than cost effectiveness alone. The results suggest a threshold somewhat higher than NICEs stated 'range of acceptable cost effectiveness' of pound 20,000-30,000 British pounds per QALY--although the exact meaning of a 'range' in this context remains unclear.

Related Papers

• → Expertise, experience, and excellence. Twenty years of patient involvement in health technology assessment at NICE: an evolving story(2020)21 cited
• → PCN154 A COMPARISON OF HTA RECOMMENDATIONS FOR CANCER TREATMENT TECHNOLOGIES PUBLISHED BY AGENCY FOR HEALTH TECHNOLOGY ASSESSMENT (AHTAPOL) AND NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE (NICE)(2010)1 cited
• Implementation of UK NICE's technology evaluation and clinical guidelines and its implication(2011)
• → PHP324 - NICE: A MULTIPROGRAM HTA ORGANIZATION TO SUIT ALL?(2018)
• → HTA260 Informal Carer Disutility: How Many Caregivers Are Captured in Cost-Utility Analyses of Treatments for Rare Diseases Submitted for NICE Highly Specialised Technology Appraisals?(2022)